Amylyx Pharmaceuticals (AMLX) Tax Provisions (2022 - 2025)

Amylyx Pharmaceuticals' Tax Provisions history runs 4 years deep, the most recent figure standing at $46000.0 for Q4 2025.

• On a quarterly basis, Tax Provisions rose 100.07% year-over-year to $46000.0 in Q4 2025; TTM through Dec 2025 was $46000.0, a 100.07% increase from a year earlier, with the FY2025 full-year figure at $46000.0, up 100.07% from the prior year.
• Tax Provisions improved to $46000.0 in Q4 2025 per AMLX's latest filing, from -$63.7 million in the prior quarter.
• Across five years, Tax Provisions topped out at $1.9 million in Q2 2023 and bottomed at -$63.7 million in Q4 2024.
• The 4-year median for Tax Provisions is $200000.0 (2022), against an average of -$5.2 million.
• Across the five-year window, Tax Provisions jumped 1314.4% in 2023 and tumbled 3749.91% in 2024, its largest moves.
• Year by year, Tax Provisions stood at $579000.0 in 2022, then jumped by 201.38% to $1.7 million in 2023, then tumbled by 3749.91% to -$63.7 million in 2024, then soared by 100.07% to $46000.0 in 2025.
• Per Business Quant, the three latest AMLX Tax Provisions figures stand at $46000.0 (Q4 2025), -$63.7 million (Q4 2024), and $242000.0 (Q1 2024).